Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$19.53
-3.8%
$19.84
$14.57
$25.11
$618.01M1.06286,668 shs408,827 shs
LifeMD, Inc. stock logo
LFMD
LifeMD
$14.76
-2.0%
$9.78
$3.99
$15.34
$684.44M2.421.05 million shs2.83 million shs
Personalis, Inc. stock logo
PSNL
Personalis
$6.42
-1.7%
$4.70
$1.14
$7.20
$576.76M1.861.07 million shs2.02 million shs
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
$2.39
+0.4%
$2.72
$0.13
$3.50
$212.38M0.131.04 million shs2.39 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-3.79%-5.61%-3.70%+14.28%-1.26%
LifeMD, Inc. stock logo
LFMD
LifeMD
-1.99%+18.46%+37.05%+163.57%+87.55%
Personalis, Inc. stock logo
PSNL
Personalis
-1.68%+6.82%+36.02%+80.34%+409.52%
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
+0.42%-3.24%-10.49%+139.91%+487.08%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
3.7977 of 5 stars
2.34.00.04.11.43.30.6
LifeMD, Inc. stock logo
LFMD
LifeMD
1.2922 of 5 stars
1.54.00.00.02.41.70.6
Personalis, Inc. stock logo
PSNL
Personalis
3.9576 of 5 stars
2.53.00.04.23.22.50.6
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
2.2 of 5 stars
3.55.00.00.00.01.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
2.50
Moderate Buy$24.0022.89% Upside
LifeMD, Inc. stock logo
LFMD
LifeMD
3.00
Buy$12.00-18.70% Downside
Personalis, Inc. stock logo
PSNL
Personalis
3.00
Buy$7.6719.42% Upside
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
3.00
Buy$7.00192.89% Upside

Current Analyst Ratings Breakdown

Latest TOI, FLGT, LFMD, and PSNL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $18.00
5/15/2025
Personalis, Inc. stock logo
PSNL
Personalis
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
5/15/2025
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$7.00
5/7/2025
Personalis, Inc. stock logo
PSNL
Personalis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$8.00 ➝ $9.00
5/6/2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$16.00 ➝ $23.00
5/5/2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$24.00 ➝ $25.00
4/30/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
4/10/2025
Personalis, Inc. stock logo
PSNL
Personalis
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$283.47M2.10N/AN/A$36.92 per share0.53
LifeMD, Inc. stock logo
LFMD
LifeMD
$212.45M3.16N/AN/A($0.09) per share-164.00
Personalis, Inc. stock logo
PSNL
Personalis
$84.61M6.70N/AN/A$2.87 per share2.24
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
$393.41M0.54N/AN/A$0.05 per share47.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$42.71M-$1.33N/AN/AN/A-13.94%-2.19%-2.02%8/1/2025 (Estimated)
LifeMD, Inc. stock logo
LFMD
LifeMD
-$18.88M-$0.34N/A123.00N/A-4.58%N/A-15.19%8/6/2025 (Estimated)
Personalis, Inc. stock logo
PSNL
Personalis
-$81.28M-$1.29N/AN/AN/A-98.10%-48.78%-34.70%8/6/2025 (Estimated)
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
-$64.66M-$0.70N/AN/A-15.38%-445.02%-34.13%8/12/2025 (Estimated)

Latest TOI, FLGT, LFMD, and PSNL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
N/A-$0.18N/A-$0.21N/A$104.41 million
5/6/2025Q1 2025
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.04$0.01+$0.05$0.01$62.47 million$65.70 million
5/6/2025Q1 2025
Personalis, Inc. stock logo
PSNL
Personalis
-$0.23-$0.18+$0.05-$0.18$17.41 million$20.61 million
5/2/2025Q1 2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$0.18$0.04+$0.22-$0.37$71.26 million$73.46 million
3/24/2025Q4 2024
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
-$0.08-$0.14-$0.06-$0.14$109.15 million$100.27 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/AN/AN/AN/AN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
N/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/AN/AN/AN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/A
6.32
6.32
LifeMD, Inc. stock logo
LFMD
LifeMD
N/A
0.82
0.77
Personalis, Inc. stock logo
PSNL
Personalis
N/A
6.91
6.74
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
14.58
1.79
1.59

Institutional Ownership

CompanyInstitutional Ownership
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
48.06%
LifeMD, Inc. stock logo
LFMD
LifeMD
35.52%
Personalis, Inc. stock logo
PSNL
Personalis
61.91%
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
36.86%

Insider Ownership

CompanyInsider Ownership
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
31.76%
LifeMD, Inc. stock logo
LFMD
LifeMD
18.40%
Personalis, Inc. stock logo
PSNL
Personalis
3.80%
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
8.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
1,31330.44 million20.78 millionOptionable
LifeMD, Inc. stock logo
LFMD
LifeMD
23045.45 million37.09 millionOptionable
Personalis, Inc. stock logo
PSNL
Personalis
40088.32 million84.97 millionOptionable
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
66089.23 million81.65 millionNot Optionable

Recent News About These Companies

Q1 2025 Oncology Institute Inc Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fulgent Genetics stock logo

Fulgent Genetics NASDAQ:FLGT

$19.53 -0.77 (-3.79%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$19.56 +0.02 (+0.13%)
As of 06/20/2025 06:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

LifeMD stock logo

LifeMD NASDAQ:LFMD

$14.76 -0.30 (-1.99%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$14.80 +0.04 (+0.30%)
As of 06/20/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.

Personalis stock logo

Personalis NASDAQ:PSNL

$6.42 -0.11 (-1.68%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$6.44 +0.01 (+0.23%)
As of 06/20/2025 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Oncology Institute stock logo

Oncology Institute NASDAQ:TOI

$2.39 +0.01 (+0.42%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$2.47 +0.08 (+3.35%)
As of 06/20/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.